Last updated on December 2018

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Brief description of study

This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body or cannot be removed by surgery, including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.

Detailed Study Description


I. To determine the objective response rate (ORR) of cediranib (cediranib maleate) plus olaparib in combination in patients with advanced or metastatic solid tumors of the following tumor types: non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC), and small cell lung cancer (SCLC).


I. To assess the safety and tolerability of oral administration of cediranib in combination with olaparib in patients with select advanced solid tumors.

II. To estimate progression free survival (PFS) in each tumor cohort.


I. To estimate the prevalence of the mutations of deoxyribonucleic acid (DNA) repair genes in tumors using the BROCA panel and to correlate tumor regression with mutations status. (Integrated) II. To evaluate changes in tumor hypoxia on cediranib treatment compared to baseline by [F-18] fluoromisonidazole (FMISO) positron emission tomography/computed tomography (PET/CT) in patients with NSCLC.

III. To evaluate levels of angiogenesis/inflammatory markers including VEGF at baseline and on treatment.

IV. To evaluate levels of circulating tumor deoxyribonucleic acid (ctDNA) at baseline and on treatment.


Patients receive cediranib maleate orally (PO) once daily (QD) on day 1. Patients undergoing FMISO scan also receive olaparib PO twice daily (BID) beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of course 1. Courses repeat every 28 days (35 days for course 1) in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks and then every 4 weeks thereafter.

Clinical Study Identifier: NCT02498613

Contact Investigators or Research Sites near you

Start Over

Shumei Kato

UC San Diego Moores Cancer Center
La Jolla, CA United States
  Connect »

Shumei Kato

University of California San Diego
San Diego, CA United States
  Connect »

Pamela N. Munster

UCSF Medical Center-Mount Zion
San Francisco, CA United States
  Connect »

Joseph W. Kim

Smilow Cancer Center/Yale-New Haven Hospital
New Haven, CT United States
  Connect »

Joseph W. Kim

Yale University
New Haven, CT United States
  Connect »

Hatem H. Soliman

Moffitt Cancer Center
Tampa, FL United States
  Connect »

Ulka N. Vaishampayan

Wayne State University/Karmanos Cancer Institute
Detroit, MI United States
  Connect »

Dana B. Cardin

Vanderbilt University/Ingram Cancer Center
Nashville, TN United States
  Connect »

Siqing Fu

M D Anderson Cancer Center
Houston, TX United States
  Connect »

Sosipatros A. Boikos

Virginia Commonwealth University/Massey Cancer Center
Richmond, VA United States
  Connect »

Daniel J. Renouf

BCCA-Vancouver Cancer Centre
Vancouver, BC Canada
  Connect »

University Health Network-Princess Margaret Hospital
Toronto, ON Canada
  Connect »

Primo N. Lara

University of California Davis Comprehensive Cancer Center
Sacramento, CA United States
  Connect »

Ulka N. Vaishampayan

Weisberg Cancer Treatment Center
Farmington Hills, MI United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.